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Abstract
The remarkably heterogeneous nature of lung cancer has become more apparent over the last decade. In general, advanced
lung cancer is an aggressive malignancy with a poor prognosis. The discovery of multiple molecular mechanisms underlying
the development, progression, and prognosis of lung cancer, however, has created new opportunities for targeted therapy
and improved outcome. In this paper, we define ‘‘molecular subtypes’’ of lung cancer based on specific actionable genetic
aberrations. Each subtype is associated with molecular tests that define the subtype and drugs that may potentially treat it.
We hope this paper will be a useful guide to clinicians and researchers alike by assisting in therapy decision making and
acting as a platform for further study. In this new era of cancer treatment, the ‘one-size-fits-all’ paradigm is being forcibly
pushed aside—allowing for more effective, personalized oncologic care to emerge.
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Introduction
Lung cancer kills more patients than any other malignancy in
the world [1]. Early-stage disease can be treated with curative
intent although the risk for relapse is notoriously high. Unfortu-
nately, the majority of lung cancer patients present at an advanced
stage. Despite an initial response to treatment, most of these late
stage patients will eventually progress on standard therapy and die
from their disease [2]. Despite the complex nature of lung cancer
biology, its molecular underpinnings are becoming increasingly
clear [3]. The discovery of a number of these molecular alterations
underlying lung cancer has led to uniquely targeted therapies with
specific inhibitor drugs such as erlotinib and gefitinib for mutations
in the epidermal growth factor receptor (EGFR) [4,5] or crizotinib
for the gene translocation resulting in the EML4-ALK oncogene
[6].
We have previously developed a formal process for classifying a
cancer - melanoma - into molecular subtypes [7]. Molecular
subtypes are defined as those tumors containing the same set of
molecular (primarily genetic) defect(s) and their associated
pathways. The division of a cancer into subtypes is purposeful in
that each subtype has proposed treatment guidelines that include
specific assays, targeted therapies, and clinical trials. This process
produces a formal ‘molecular disease model’ that can be used by
clinicians to guide treatment decisions, and refined by researchers
based on clinical outcomes and laboratory findings.
In light of the growing insight into the molecular mechanisms
underlying lung cancer with the development of sophisticated
molecular diagnostics and targeted therapies, we now extend the
molecular subtyping approach to lung cancer. Similar to the
previously described melanoma molecular disease model, the lung
cancer molecular disease model consists of a set of actionable
molecular subtypes and proposed practice guidelines for treating
each subtype. In contrast to the melanoma model, there is a larger
molecular heterogeneity that exists within lung cancer (see
Figure 1). Therapies (approved or experimental) that should be
considered and those that are contraindicated are discussed. A
subtype is deemed actionable if there is both an approved assay to
determine whether a given tumor fits that classification and at least
one FDA-approved or experimental targeted therapy with
potential efficacy for that subtype. An example would be lung
tumors containing the EGFR exon 19 mutation for which
commercial assays and targeted agents are currently available.
The latest version of this model can be found online here:
,http://bigmac.collabrx.com/lc_edit/index.php/A_Lung_Cancer_
Molecular_Disease_Model..
The online version contains additional in-depth information
about relevant genes, genetic tests, pathways, drugs, targets, and
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format. Given the evolving state of knowledge, we anticipate this
baseline model will need to be revised routinely with new clinical
and scientific findings. Existing types are likely to be split into new
subtypes corresponding to responders and non-responders, and
new types are likely to be added to accommodate previously
unseen tumor groups. Over time, this model will be defined with
greater and greater specificity and linked to increasingly efficacious
therapies.
Results
Tables 1 and 2 summarize the subtypes of lung cancer, roughly
in order of importance of the associated oncogene/tumor
suppressor, prevalence and potential for therapeutic intervention.
The oncogenes that define the subtypes in Table 1 are currently
high ‘strength of evidence’ (SOE) and capable of serving as the
dominant oncogene and putative point of intervention for therapy,
whereas the oncogenes and tumor suppressor genes that define
subtypes in Table 2 are medium or low SOE and ‘‘on the horizon’’
for lung cancer treatment strategies. Figure 1 shows the major
signaling pathways implicated in lung cancer. It is our hope that
the present model serves to focus translational research on issues
that may directly impact patient care, and that the resulting
activity will lead to updates in the model.
Subtype 1
Subtype 1 harbors aberrations in the EGFR gene/pathway – a
set of targetable mutations with commercially available inhibitors
as well as newer agents on the horizon.
Subtype 1.1 overview
SUBTYPE 1.1 is characterized by mutations in the EGFR gene
that make these tumors responsive to EGFR inhibitors. EGFR
encodes a transmembrane receptor that is a member of the ErbB
family of tyrosine kinases. EGFR is a cell surface protein that binds
to epidermal growth factor and other growth factor ligands to
become activated [3]. Upon activation, EGFR tyrosine kinase
activity stimulates activation of downstream pathways including
Ras/MAPK and Akt/PI3K leading to DNA synthesis and cell
proliferation [8,9,10,11].
EGFR has been shown to be dysregulated by various
mechanisms in NSCLC, including overexpression, amplification
Figure 1. A major signaling pathway implicated in lung cancer is the EGFR pathway which signals to both the AKT/PI3K pathway
(green) and the MAPK pathway (red) which regulate cell growth, proliferation and cell death. There is significant cross-talk between
these pathways and their downstream effectors, which we have classified into 6 pathways for simplicity to account for differences in treatment
modalities. The additional 4 pathways are: EGFR (blue), KRAS (yellow), EML4-ALK (orange), and P53/BCL (purple). It is thought that the RAS/RAF/MEK/
MAPK pathway may be constitutively activated by the EML4-ALK fusion oncogene [100]. The complex relationship between this pathway and EML4-
ALK is indicated with a dashed line.
doi:10.1371/journal.pone.0031906.g001
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the following histologies upon cancer recurrence or metastases:
adenocarcinoma (AC) and large cell lung cancers (LC) [13].
EGFR alterations occur in ,10% of western and ,50% of Asian
patients with lung adenocarcinoma, a histology which comprises
44% of NSCLC cases [14]. Higher EGFR mutation frequency
occurs in non-smokers, women, and non-mucinous tumors. Data
from several clinical trials has indicated that patients with EGFR
mutations have improved progression free survival when treated
with EGFR inhibitors compared to patients with the same
mutations who received standard-of-care, cytotoxic chemotherapy
regimens [5,15,16]. The SOE score for determining EGFR
mutation status in patients with AC or LC histology is therefore
‘high’.
This subtype includes three classes of mutations: Class I
mutations – exon 19 in-frame deletions (44% of all EGFR
mutations), Class II - single amino acid changes (L858R 41%,
G719 4%, other missense mutations 6%), Class III - exon 20 in-
frame duplication/insertions (5%). Eighty-five percent of all
EGFR activating mutations are Class I or L858R [17]. EGFR
mutations are relatively rare (,3.6%) in squamous cell carcinoma
and EGFR testing is not routinely recommended per NCCN
guidelines [13,18].
Potential therapeutic approach for subtype 1.1
EGFR inhibitors. NSCLC large cell and adenocarcinoma
patients should be tested at diagnosis for EGFR mutations as those
who exhibit such mutations benefit from EGFR inhibitors (e.g.
erlotinib or gefitinib) in the first-line setting, as recommended by
NCCN guidelines [13]. EGFR inhibitors are playing an
increasingly important role in the treatment of NSCLC in select
patient groups with aberrantly functioning EGFR and are also
used in second- and third-line treatment [4].
Combination Therapies. Some additional trials for
recurrent or advanced NSCLC are ongoing. These trials will
test the efficacy of second-generation EGFR inhibitors or
approved EGFR inhibitors (such as erlotinib) in combination
with other inhibitor drugs such as MET/VEGFR2 inhibitors.
Subtype 1.2 – Overview
Subtype 1.2 is defined as NSCLC that harbors a T790M
mutation in exon 20 of the EGFR gene. T790M mutations emerge
in response to treatment with EGFR TKIs. The T790M mutation
accounts for approximately 50% of cases in which acquired
resistance to erlotinib or gefitinib occurs [19,20,21]. A small
percentage of patients may carry the mutation prior to EGFR TKI
treatment. Data from clinical trials have indicated the presence of
Table 1. Principle lung cancer molecular subtypes.
Sub-type Description Pathway Potentially relevant therapies
Relevant histological
subtypes
Strength of evidence
for clinical use*
1.1 EGFR sensitizing
mutations
EGFR TKIs & chemotherapy Adenocarcinoma High
1.2 EGFR resistance
mutations including
T790M
EGFR Dual EGFR/HER2 TKI, c-MET inhibitors +/2 1
st
or 2
nd generation EGFR TKIs, Hsp90 inhibitors,
dual MET/VEGFR2 inhibitors, Chk1 inhibitors
Adenocarcinoma High
1.3 VeriStrat proteomic
signature
EGFR TKIs & bevacizumab Adenocarcinoma High
2.1 K-ras mutations K-ras Dual MAPK & AKT/PI3K inhibitors, Hsp90 inhibitors Adenocarcinoma High
3.1 EML4-ALK EML4-ALK ALK inhibitors, Hsp90 inhibitors Adenocarcinoma High
doi:10.1371/journal.pone.0031906.t001
Table 2. Secondary lung cancer molecular subtypes.
Sub-
type Description Pathway Potentially relevant therapies
Relevant histological
subtypes
Strength of evidence
for clinical use*
4.1 c-MET overexpression c-MET c-MET inhibitors, Dual Met/VEGFR2
inhibitors, ALK/MET inhibitors, c-MET
monoclonal antibodies
Adenocarcinoma, small
cell carcinoma, squamous
Medium
4.2 c-MET mutations c-MET c-MET inhibitors, dual Met/VEGFR2
inhibitors, ALK/MET inhibitors, c-MET
monoclonal antibodies
Adenocarcinoma,
squamous, large cell,
small cell carcinoma
Low
5.1 PI3KCA amplification, mutations AKT/PI3K PI3K, AKT, mTOR inhibitors Adenocarcinoma Low
5.2 PTEN deletions/methylation AKT/PI3K PI3K, AKT, mTOR inhibitors Adenocarcinoma Low
6.1 VEGFR overexpression VEGFR VEGFR inhibitors Small cell carcinoma Low
6.2 Bcl-2 overexpression P53/BCL BCL-2 Inhibitors Small cell carcinoma Low
7.1 ROS1 translocation ROS-1 ROS1 inhibitors Adenocarcinoma (1.5%) Medium
8.1 Epigenetic alterations HDAC inhibitors, epigenetic inhibitors
with cytotoxic agents
-L o w
9.1 IGF alterations IGF IGF1R monoclonal antibodies, IGF1R TKIs Adenocarcinoma, Squamous,
SCLC
doi:10.1371/journal.pone.0031906.t002
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inhibitors [22]. The SOE score for testing patients with EGFR
mutant adenocarcinoma who have developed EGFR TKI
resistance is therefore ‘high’.
EGFR TKIs (such as erlotinib or gefitinib) are selective inhibitors
of EGFR’s kinase domain that work by competing with ATP for
binding at the ATP-binding site, thereby preventing autophospho-
rylationand activation.TheT790Mmutationaffectsthegatekeeper
residue inthecatalytic kinasedomainandconfersdrug resistanceby
increasing EGFR’s affinity for ATP – thus reducing the potency of
the ATP-competitive kinase inhibitors [23].
Interestingly, the development of a T790M mutation may
actually confer a relatively improved survival, as tumors that
acquire it appear to be less aggressive than tumors with EGFR
TKI resistance due to other mechanisms [21]. Other aberrations
that may give rise to EGFR TKI resistance include PIK3CA
mutations, EMT or MET amplification, or conversion to small cell
lung cancer histology [3,24]. Thus, for patients who progress on
EGFR TKIs with initial response and known mutation, it would
be beneficial to perform a repeat biopsy.
Potential therapeutic approach for subtype 1.2
Several treatment modalities for addressing drug resistance due
to the EGFR T790M mutation are currently being explored.
Second Generation EGFR Inhibitors. The first strategy
employs second generation TKI’s such as afatinib (BIBW2992)
that irreversibly inhibits human epidermal growth factor receptor
2 (Her2) and EGFR kinases. Preclinical data have demonstrated
that afatinib is a potent irreversible inhibitor of EGFR/HER1/
ErbB1 receptors including the T790M variant [25].
MET inhibitors. While secondary mutations in EGFR are
responsible for the majority of cases of acquired EGFR TKI
resistance, activation of other pathways can also lead to resistance.
For example, c-MET amplification has been observed in
approximately 5%–20% of patients with acquired resistance to
EGFR inhibitors. A second therapeutic strategy thus adds various
drugs or antibodies capable of inhibiting c-MET (e.g. crizotinib,
foretinib, ARQ 197, MetMAb) to first- (erlotinib) or second- (PF-
00299804) generation EGFR-TKIs [26,27,28]. c-MET is a proto-
oncogene that encodes a protein known as hepatocyte growth
factor receptor (HGFR) that possesses tyrosine-kinase activity.
Recent research has indicated a reciprocal and complementary
relationship between T790M and MET amplification. Concurrent
inhibition of both may improve patient outcomes [29]. There is
also data to support that an antibody against c-MET (MetMAb) is
beneficial to patients with high expressing c-MET in combination
with erlotinib [30].
Hsp90 inhibitors. A third approach involves inhibition of
the molecular chaperone Hsp90 with Hsp90 inhibitors such as
AUY922, and possibly ganetespib (STA9090). The molecular and
cellular consequences of Hsp90 inhibition are not well defined, but
some cancers increase levels of active Hsp90, utilizing Hsp90 to
process mutant or misexpressed proteins [31,32]. Hsp90 inhibitors
may thus block multiple signaling pathways that are functioning
aberrantly in cancer cells [33].
Combination Therapies. Some additional trials for
recurrent or advanced NSCLC are ongoing. These trials will
test the efficacy of various combination therapies including EGFR
inhibitors, second- generation tyrosine kinase inhibitors, a dual
MET/VEGFR2 inhibitor, a Chk1 inhibitor and more.
Subtype 1.3 Overview
SUBTYPE 1.3 tumors are defined based on a proteomic
signature called VeriStrat, which provides likely responsiveness to
EGFR inhibitory therapies such as erlotinib in the absence of
EGFR mutations.
VeriStrat utilizes mass spectrometry to evaluate tumor EGFR
ligand levels and predict patient response and survival outcome to
erlotinib and other EGFR inhibitors from serum samples
[34,35,36].
VeriStrat profiling is an approved serum analysis diagnostic tool
for NSCLC patients who have tested negative for EGFR mutation
since some patients with wildtype EGFR status may still benefit
from erlotinib treatment regimens. Several recent studies have
indicated that VeriStrat classification has significant power to
predict response and survival to EGFR inhibitors for several
cancer types [34,35,36]. The SOE score for VeriStrat classification
for patients with wild type EGFR status is ‘high’. One study found
that 73% of EGFR wt NSCLC patients previously administered
erlotinib had a ‘‘VeriStrat good’’ status. The ‘‘VeriStrat good’’
patients had increased survival after erlotinib treatment compared
to the ‘‘VeriStrat poor’’ group [34]. This is thought to be based
upon tumor dependence on the EGFR pathway [36].
Potential therapeutic approach for SUBTYPE 1.3
EGFR inhibitors. Patients with a ‘‘VeriStrat good’’ status are
predicted to respond well to EGFR inhibitors and should pursue
second- and third-line therapy for EGFR positive NSCLC as
outlined by several reputable organizations including ASCO and
the NCCN [13,37]. EGFR inhibitors are playing an increasingly
important role in the treatment of NSCLC in select patient groups
with aberrantly functioning EGFR [3].
Second Generation EGFR inhibitors. As noted earlier, the
dual EGFR and Her2 inhibitor BIBW 2992 is currently being
tested in a phase 2 and 3 clinical trial to explore efficacy in patients
with lung adenocarcinoma harboring wildtype EGFR [38].
Subtype 2
SUBTYPE 2.1 is characterized by mutations in the K-ras gene.
K-ras belongs to a family of small GTPases that regulate cellular
behavior in response to extracellular stimuli. Ras-regulated signal
pathways control processes such as actin cytoskeletal integrity,
proliferation, differentiation, cell adhesion, apoptosis, and cell
migration via the MAPK and AKT/PI3K pathways [8,39].
Ras has many isoforms of which K-ras and N-ras and the most
relevant to human cancer and are estimated to be mutated in 20–
30% of all cancers [40]. While these isoforms are functionally
similar, they appear to play unique roles in particular cancers [41].
For example, H-ras aberrations are frequently observed in bladder
cancer [42], and N-ras is mutated in approximately 20% of
melanomas [43,44]. K-ras mutations are observed primarily in
adenocarcinomas of the lung, colon or pancreas [45].
Subtype 2.1 overview
Subtype 2.1 is the only subtype in this category and is
characterized by mutations in K-ras. K-ras proteins possess
intrinsic GTPase activity. Point mutations at codons 12, 13, or
60 in the K-ras oncogene lead to constitutive activation of K-ras
protein via changes at the GTP binding domain which prevents
the conversion of GTP to GDP [3,46]. Overall, K-ras mutations
have been reported in 15% to 20% of all patients with NSCLC.
Approximately 30%–50% of adenocarcinomas are reported to
have K-ras mutations, with mutations at codon 12 most commonly
detected [3,14]. K-ras mutations are seen almost exclusively in
smokers with one study reporting that 43% of smokers who
developed NSCLC had a K-ras mutation compared to 0% of life-
long non-smokers with NSCLC [47]. Squamous cell carcinomas
are not reported to exhibit K-ras mutations [48].
Molecular Subtypes of Lung Cancer
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A meta-analysis that included 28 studies of NSCLC reported
worse outcomes for patients with K-ras mutations, particularly
those with adenocarcinoma histology [46]. K-ras mutations in
NSCLC are associated with decreased response to EGFR TKIs.
However, K-ras and EGFR mutations are almost always mutually
exclusive and the lack of response to EGFR TKIs is most likely
due to the absence of an EGFR mutation as opposed to the
existence of a K-ras mutation [29]. The SOE score for testing
adenocarcinoma patients for K-ras mutations is ‘high’.
MEK and mTOR inhibitors. Despite the widespread
impact of Ras mutations on cancer, Ras has not been
successfully targeted therapeutically in NSCLC. However,
several approaches are currently being tested in clinical trials.
The first involves concurrently targeting the downstream MAPK
and AKT/PI3K pathways [8,10]. Kinase inhibitors (such as MEK
or MTOR inhibitors) that target kinases in pathways downstream
of Ras may thus be effective against K-ras mutant cells [49].
HSP90 inhibitors. A second approach involves inhibition of
the molecular chaperone Hsp90. As noted earlier, HSP90
inhibitors may block multiple signaling pathways that are
functioning aberrantly in cancer cells [33].
REOLYSIN therapy. REOLYSIN is a proprietary
formulation of human reovirus in development by Oncolytics
Biotech Inc. for various cancers. REOLYSIN (Reovirus Serotype
3 - Dearing Strain) is a naturally occurring oncolytic virus that
preferentially lyses cancer cells, specifically those that have
upregulated RAS signaling. The preferential lysis of Ras
activated cells and the non-pathogenic nature of the reovirus
[50] make REOLYSIN an attractive therapeutic option for
Subtype 2.1 K-ras mutant patients. REOLYSIN is in phase 2
clinical trials for NSCLC and phase 1 and 2 clinical trials for
multiple other cancers including melanoma, colorectal cancer,
osteosarcoma, and more.
Subtype 3
The EML4-ALK oncogene is a relatively newly-discovered
aberration in NSCLC with several targeted agents in active
development, including crizotinib which was recently FDA-
approved for this subtype [6,51].
Subtype 3.1 Overview
Subtype 3.1 is the only subtype in this category and it harbors
the EML4-ALK fusion oncogene, a fusion between echinoderm
microtubule-associated protein-like 4 (EML4) and anaplastic
lymphoma kinase (ALK) [6]. The fusion generates a transforming
tyrosine kinase, with as many as nine different variants identified
[52]. Several isoforms play a role in lung cancer [53,54]. EML4-
ALK represents a novel molecular target in a small subset of
NSCLCs. Patients with EML4-ALK mutant tumors are charac-
teristically younger, female, and never to light smokers [6,55,56].
The fusion gene has been observed predominantly in adenocar-
cinomas (4–7%) and is mutually exclusive with mutations in the
EGFR, K-ras, and ERBB2 genes [6,56]. Interestingly, ALK
fusions have also been described in anaplastic lymphomas and in
about 50% of inflammatory myofibroblastic tumors (IMTs) with
EML4 [3,57]. The SOE score for testing adenocarcinoma patients
for the EML4-ALK translocation is ‘high’.
Potential therapeutic approach for SUBTYPE 3.1
ALK inhibitors. EML4-ALK NSCLC represents a unique
subset of NSCLC patients for whom ALK inhibitors have high
potential as a very effective therapeutic strategy [6]. Patients who
harbor the EML4-ALK fusion do not benefit from EGFR TKIs
and should be directed to trials of ALK-targeted therapies [58].
Crizotinib has been approved by the FDA [51], and LDK378 is in
development for EML4-ALK NSCLC. Of note, mutations within
ALK that lead to crizotinib resistance have already been
described, analogous to the T790M mutation leading to
erlotinib and gefitinib resistance in EGFR [59].
Hsp90 inhibitors. The Hsp90 inhibitor IPI-504 is currently
in clinical trials to test its efficacy in lung cancer patients with ALK
mutations. As noted earlier, HSP90 inhibitors may block multiple
aberrantly functioning signaling pathways in cancer cells [33].
Ganetespib (STA-9090) is also being utilized in clinical trials
against ALK translocated lung cancer patients.
Subtype 4
Subtype 4 harbors aberrations in c-MET. c-MET is a proto-
oncogene with important implications in NSCLC [3,60]. Multiple
agents are in active development to target this pathway.
Subtype 4.1 overview
SUBTYPE 4.1 is characterized by dysregulation of mesenchy-
mal-epithelial transition factor receptor tyrosine kinase (noted as c-
MET). c-MET is a proto-oncogene that encodes a tyrosine kinase
membrane receptor known as hepatocyte growth factor receptor
(HGFR) [60]. Much of c-MET’s oncogenic activity stems from its
normal physiologic role. In healthy cells c-MET promotes cell
growth and cell migration. However, dysregulation of the c-MET
pathway leads to cell proliferation, cell survival, angiogenesis,
invasion and metastasis [61]. c-MET dysregulation can occur
through a variety of mechanisms including c-MET overexpression,
activation, overexpression of the c-MET ligand hepatocyte growth
factor (HGF), gene amplification, and c-CBL loss of heterozygosity
[60,62]. These alterations, discussed below, are currently grouped
together in subtype 4.1. Tests for the detection of all of these
abnormalities are not yet considered FDA approved biomarkers,
nor is c-MET yet considered a predictive marker that informs
clinical decision making for lung cancer patients. Data from
clinical trials testing c-MET targeted therapies in genetically
selected patient subsets will hopefully increase the SOE score from
medium to high in the near future.
c-MET overexpression has been observed in 67% of adenocar-
cinomas, 57% of large cell carcinomas, 57% of squamous cell
carcinomas, and 25% of small cell lung cancers [63]. A recent
study demonstrated that adenocarcinoma tumors had a significant
increase in the number of MET gene copies indicating that gene
amplification is one possible mechanism underlying c-MET
overexpression [64]. c-MET activation occurs concomitantly with
overexpression and can be detected using immunohistochemical
staining for c-MET (called p-MET for detection of phosphoryla-
tion typically at sites Y1003 or Y123/1234/1235) [63,65].
The c-MET ligand HGF can also be overexpressed by tumor
cells with moderate expression observed in 45% of lung cancer
tumors [66]. When HGF binds to the c-MET receptor it generates
MET autophosphorylation leading to activation of the MET
pathway enabling cell mobilization and vascularization – two
processes that contribute to tumor malignancy [3,60].
Finally, c-MET dysregulation may also occur through gene
mutation. This aberration is clearly distinguishable from the others
by gene sequencing [60] and has been assigned to Subtype 4.2.
Subtype 4.2 overview
Subtype 4.2 is characterized by mutations of c-MET.
c-MET mutations have been observed in both NSCLC and
small cell lung cancer. The prevalence of c-MET mutations is
relatively low compared to the frequency of c-MET overexpres-
Molecular Subtypes of Lung Cancer
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progression has been shown to be significant [60]. Mutations are
found in two different domains of the c-MET receptor protein.
One study of four NSCLC lines and 127 adenocarinomas
identified four missense mutations (E168D, L229F, S323G,
N375S) in the semaphorin domain, a structural domain of
semaphorins, which are a large family of secreted and transmem-
brane proteins. Another group of mutations were found in the
juxtamembrane domain including: R988C and T1010I, S1058P,
and an alternative splice variant (lacking the 47-amino acid exon
14) which affects the juxtamembrane domain [63]. Juxtamem-
brane mutations are significant because this domain is an
important regulatory site for the catalytic functions of tyrosine
kinases. Mutations in this region resulted in constitutive protein
tyrosine phosphorylation and enhanced tumorgenicity in vitro.
E168D (sema domain), and R988C and T1010I (juxtamembrane
mutations) were also observed in SCLC [66].
Another aberration recently observed to positively correlate
with c-MET mutation in NSCLC cell lines is mutation of the
Casitas B-lineage lymphoma (c-CBL) gene [62]. c-CBL is a
ubiquitin ligase and adaptor ligase that plays a role in normal
homeostasis. The high rate of mutation of c-CBL observed in lung
cancer is thought to be a combination of somatic missense
mutation and loss of heterozygosity (LOH) at the c-CBL locus
[3,60,62]. c-CBL LOH is associated with mutations in either the
MET or EGFR genes as these events have been observed to co-
occur in the same samples. It is thus hypothesized that c-CBL
mutations may combine with either a MET alteration or EGFR
mutation to contribute to lung tumorigenesis and metastasis [62].
Due to a low SOE for c-CBL as a predictive biomarker in the
clinical setting, it has not yet been assigned its own subtype.
It should also be noted that MET mutations vary along ethnic
and racial lines. One recent study found the highest frequency of
c-MET mutations in East Asians. The N375S sema domain
mutation was found to be the most frequent mutation overall,
occurring more frequently in East Asians than Caucasians, and
never in African-American samples [67].
Potential therapeutic approach for SUBTYPE 4
MET inhibitors. Several targeted therapies for the treatment
of aberrant MET activity are currently in clinical testing. The first
strategy employs direct MET inhibitors capable of interfering with
c-MET signaling. Several - including ARQ 197, cabozantinib, and
foretinib – are currently in phase 2 and 3 clinical trials.
MET antibodies. A single-arm antibody directed against the
extracellular domain of MET, called MetMAb, has been tested in
a randomized phase II study in patients with previously treated
NSCLC with erlotinib. In the intent-to-treat analysis, no benefit
was seen with the addition of MetMAb to erlotinib compared to
those treated with erlotinib alone. However, in those patients with
‘‘MET diagnostic-high’’ criteria on immunohistochemistry (a
composite of intensity and extent of staining that was seen in
approximately 50% of patients), there was improvement in
progression-free and overall survival, leading to the initiation of
a phase III study in this subset of patients [30].
HGF antibodies. Two HGF antibodies that target the
aberrant action of HGF are currently being tested in lung
cancer patients. AMG-102 is a human monoclonal antibody that
is in phase I and II clinical trials for NSCLC and several other
cancers. Data from one trial in patients with advanced solid
tumors suggests that AMG-102 is well tolerated and may inhibit
tumor progression in some patients [68]. A second HGF antibody
AV-299 is in development by AVEO Pharmaceuticals. Data from
phase 1 clinical trials in several cancer types have indicated that
AV-299 is tolerable and can be combined favorably with EGFR
inhibitors such as erlotinib and gefitinib. Data on the efficacy of
AV-299 in treatment of NSCLC should be available toward the
end of 2011.
Hsp90 Inhibitors. Another strategy involves inhibition of the
chaperone protein, Hsp90, which is required for c-MET protein
(and other kinase) folding and stability [3]. AUY922 and IPI-504
are currently in phase 1 and 2 clinical trials for lung cancer.
Subtype 5
Subtype 5 harbors aberrations in the AKT/PI3K pathway.
PI3K acts antagonistically with the lipid phosphatase, PTEN, to
tip the balance between two signaling molecules, PIP2 and PIP3
[69,70]. Upon growth factor stimulation, PI3KCA is activated
increasing PIP3 levels which drives phosphorylation of AKT and
downstream processes such as higher protein translation, cell
division and reduced apoptosis [10,69].
Subtype 5.1 overview
Subtype 5.1 is characterized by aberrations in PI3K, a lipid
kinase that regulates growth in the AKT/PI3K pathway. The
PI3K protein family is divided into three classes and several
subclasses based on primary structure, regulation, and in vitro lipid
substrate specificity. Of these the Class Ia is the most studied,
partly because of its role in cancer. These proteins are composed
of a catalytic subunit known as p110 and a regulatory subunit
known as p85. To date the PI3K is the only family member found
to have somatic mutations in human cancer. These mutations
occur predominantly in the helical or kinase domains of the alpha
p110 catalytic subunit which is encoded by the PI3KCA gene [71].
The PI3K/AKT pathway plays a key role in regulating
mammalian cell proliferation and survival. Activating mutations
in PI3KCA have been implicated in various cancers including
melanoma, breast cancer, colorectal cancer and NSCLC. In lung
cancer, PI3KCA gene amplification occurs at a much higher
frequency than do activating mutations [69,71]. According to one
study, PI3KCA copy number gain was found in ,33% of
squamous cell tumors, ,6.2% of adenocarcinomas, and ,2% of
SCLC tumors. Mutations were found in 3.6% of SCC, 2.6% of
AC, but not in SCLC [71]. Exon 9 was most frequently mutated
site in AC and SCC. Exon 20 was also affected, though more
frequently in AC than in SCC [18,71]. The SOE score for genetic
testing for PI3K aberrations in lung cancers is currently ‘low’ since
only data from pre-clinical models are available.
Potential therapeutic approach for SUBTYPE 5.1
There are three potential targets for therapeutic intervention in
this pathway: AKT, PI3K, and mTOR. There are several drugs in
clinical development against all three targets and a few drugs
against mTOR that are currently approved for other cancer types.
PI3K inhibitors. Several phase I and II trials are currently
ongoing targeting PI3K in NSCLC either alone or in combination
with standard, cytotoxic chemotherapy. These agents include
XL765 – which also inhibits mTOR – BKM120, and GDC-0941.
AKT inhibitors. Phase I and II trials are currently recruiting
that offer MK-2206 – an oral, potent, allosteric inhibitor of AKT –
in combination with either erlotinib or gefitinib in advanced
NSCLC.
mTOR inhibitors. Multiple phase I and II trials are
recruiting patients for treatment of advanced NSCLC with
mTOR inhibition either alone or in combination with
chemotherapy or radiation therapy. These include agents such
as everolimus, sirolimus, and temsirolimus as well as agents that
have dual mTOR and PI3K activity such as XL-765.
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Subtype 5.2 harbors inactivating mutations or deletions in
PTEN, a lipid phosphatase that negatively regulates growth
through the AKT/PI3K pathway, as noted above [69,70].
Inactivation of PTEN is associated with a variety of cancers
including glioblastoma, melanoma, prostate, breast, endometrial
cancers, and NSCLC. Loss of the PTEN tumor suppressor results
in tumorigenesis. PTEN mutations (in exons 5–8) have been
observed in 8% of SCC and 1% of adenocarcinomas [72]. The
SOE score for genetic testing for PTEN aberrations is currently
‘low’ since only data from pre-clinical models are available.
Potential therapeutic approach for Subtype 5.2
Same as seen for Subtype 5.1.
Subtype 6
This subtype is characterized by aberrations in the vascular
endothelial growth factor (VEGF) pathway. The VEGF pathway
regulates vascular angiogenesis. Tumors usurp this pathway to
promote self survival and proliferation. Downstream of VEGF, B-
cell lymphoma 2 (Bcl-2) is an anti-apoptotic regulator protein that
has been implicated in a number of cancers including SCLC.
VEGF can promote the survival of tumor cells through the
induction of Bcl-2 expression [73] which in turn can induce VEGF
expression in certain tumor types [74,75,76].
Subtype 6.1 overview
SUBTYPE 6.1 is characterized by overexpression of vascular
endothelial growth factor receptor (VEGFR). VEGFR is the
receptor for vascular endothelial growth factor (VEGF), an
important signaling protein involved in vasculogenesis and angio-
genesis. Aberrations in the VEGFR pathway contribute to the rapid
growth and high metabolic activity characteristic of SCLC and are
associated with poor outcome for this cancer type [77]. The SOE
score for genetic testing for VEGFR aberrations in SCLC is
currently ‘low’sinceonly data frompre-clinicalmodelsare available.
Potential therapeutic approach for Subtype 6.1
VEGFR inhibitors. Current trials evaluating VEGFR
inhibition in SCLC include the agents vandetanib and sunitinib,
either in combination with cytotoxic chemotherapy or as
maintenance therapy. To date, trials done in unselected patients
have been disappointing. Future biomarker directed trials based
upon serious biologic rational are needed to determine the true
efficacy of these inhibitors in select patient groups.
Subtype 6.2 overview
Subtype 6.2 is characterized by aberrations in Bcl-2, a key
inhibitor of cell apoptosis. The Bcl-2 family of proteins contains
both pro- and anti-apoptotic members which regulate apoptosis
via a delicate balance. The Bcl-2 pathway is activated in response
to cellular stress such as growth factor deprivation, hypoxia, cell
detachment or DNA damage via p53.
Several lines of evidence point to a key role of Bcl-2 in SCLC
pathogenesis:
1. Bcl-2 has been reported to be up-regulated in 73%–90% of
human SCLC tumors [78,79,80].
2. Anti-sense suppression of Bcl-2 leads to decreased survival of
SCLC cell lines and increased sensitivity to chemotherapy [81].
3. Targeted inhibition of Bcl-2 using small molecule inhibitors
killed SCLC cell lines treated in vitro and caused regression of
established tumors in xenograft models (mice) [82,83,84].
The SOE score for genetic testing for Bcl-2 aberrations in
SCLC is currently ‘low’ since only data from pre-clinical models
are available.
Potential therapeutic approach for Subtype 6.2
Several drugs that could provide therapeutic relief to this
subtype of patients, including YM155, ABT-737, AT-101 and
TW37, are in the early stages of development. The drug classes
discussed here are also good candidates for targeted therapies for
SCLC patients.
Bcl-2 inhibitors. One anti-apoptotic agent, oblimersen, an
anti-sense agent targeted at nuclear Bcl-2 has exhibited mixed
results for SCLC. A small phase I study reported a promising
response rate of 83% (10 of 12 evaluable patients) for oblimersen
with paclitaxel in patients with chemorefractory relapsed SCLC,
based on observations that Bcl2 family members contribute to
paclitaxel resistance. A follow-up phase II study tested carboplatin
and etoposide with or without oblimersen and the addition of
oblimersen neither improved patient response rate nor survival
[84,85].
Hedgehog inhibitors. Phase I and II trials treating SCLC
with Hedgehog inhibition alone or in combination with standard
cytotoxic chemotherapy are currently ongoing. These agents
include GDC-0449 and XL-139.
Picornavirus. Picornaviruses are non-enveloped, positive-
stranded RNA viruses with an icosahedral capsid. One
particular picornavirus, Seneca Valley Virus-001, is a biologic
agent which may have anti-neoplastic activity on its own. A phase
II trial is currently ongoing in which patients with extensive-stage
SCLC are randomized to Seneca Valley Virus-001 versus placebo
after induction cytotoxic chemotherapy.
Subtype 7
The recent discovery of ROS-1 mutations has shown that drugs
such as crizotinib may have more activity than the already known
inhibition of the EML4-ALK translocation and c-MET.
Subtype 7.1 overview
SUBTYPE 7.1 harbors the ROS-1 translocation. Patients with
ROS-1 mutant tumors are characteristically young, non-smokers.
The fusion gene has been observed predominantly in adenocar-
cinomas (,1.5%) and is mutually exclusive with mutations in the
EGFR, K-ras, and EML4-ALK genes [56]. The SOE score for
testing adenocarcinoma patients for the EML4-ALK translocation
is ‘medium’.
Potential therapeutic approach for SUBTYPE 7.1
Crizotinib. ROS1 NSCLC represents a unique subset of
NSCLC patients for whom the c-MET/ALK inhibitor crizotinib
has shown potential as a very effective therapeutic strategy. As
noted earlier, the ALK inhibitors crizotinib and LDK378 are
currently in development for EML4-ALK NSCLC though at
present, only crizotinib has been shown to be effective in treating
this small subset of patients with a ROS1 translocation [54]. A
phase I trial evaluating crizotinib in advanced solid tumors which
possess the ROS1 translocation is currently ongoing.
Subtype 8.1 overview
Subtype 8.1 involves epigenetic alterations. Epigenetics is the
study of reversible changes to DNA and the nucleosome that affect
expression of genes and can be pharmacologically manipulated.
The earliest recognized of these changes was DNA methylation. In
tumors, it was found that methylation at the 5 position of cytosines
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a relative over-abundance of cytosine-guanine dinucleotides) led to
decreased expression of affected genes, often tumor suppressor
genes or other growth regulatory molecules. This process is
complex and is controlled by DNA methyltransferase inhibitors,
DNMT1, DNMT3a and DNMT3b. Hypermethylation of pro-
moter regions in cancer, specifically lung cancer is an almost
universal finding, with differences in different types of cancer [86].
Methylation inhibitors, typically nucleotide analogues were found
to be capable of inhibiting DNA methyltransferases, demethylat-
ing DNA and leading to gene re-expression. Several nucleoside
analogues, 5-azacytidine and 5-aza, 29-deoxycytidine have been
found to be effective in the treatment of mylodysplastic syndromes
and leukemias and are FDA approved for these indications [87].
Control of gene expression is more complex such that in
addition to DNA methylation, changes in the nucleosomal
structure via post-translational modifications of histones, specifi-
cally methylation, acetylation, phosphorylation and sumoylation at
the amino terminus of histone H3 and histone H4 can also lead to
alterations of gene expression. The interplay between DNA
methylation and histone post-translational modifications is com-
plex, and includes histone methyltransferases and acetyltransfer-
ases as well as deacetylases. Typically, more heavily acetylated
histone tails leads to a more ‘‘open’’ chromatin configuration and
is more accessible to transcription factors and the basal
transcriptional machinery. In vitro experiments have shown that
histone deacetylase inhibitors (therefore leading to more heavily
acetylated histones) leads to greater expression of target genes, and
several HDAC inhibitors have been evaluated in clinical trials
showing activity particularly in cutaneous T cell lymphoma [88].
Combination therapy with methylation inhibitors and HDAC
inhibitors has attraction given that a number of preclinical in vitro
experiments have demonstrated dramatic synergistic effects in
terms of gene expression as well as other cellular effects when these
epigenetic modifying agents are combined [87,89]. Recent
experiments have demonstrated that HDACs affect the acetylation
status of more than histones, and that a number of other important
cellular proteins are also subject to these post-translational
modifications. These proteins include tubulin, p53, E2F and
others. The relevance of these proteins in the effect of HDAC
inhibitors on tumor cells has not been fully evaluated.
Potential Therapeutic Approach to SUBTYPE 8.1
A number of trials have attempted to utilize epigenetic therapy
including DNA methylation inhibitors, HDAC inhibitors, the
combination of methylation inhibitors and HDAC inhibitors as
well as epigenetic agents combined with standard cytotoxic agents.
One of the great questions in epigenetic therapy is whether there
are specific patients who are more likely to benefit from these
therapeutic agents.
Subtype 9
This subtype is characterized by aberrations in the insulin-like
growth factor (IGF) axis. This axis involves two receptors (IGF1R
and IGF2R), their ligands (IGF-1 and IGF-2), and multiple
binding proteins. It is theorized that defects in the IGF axis are
involved in the development of multiple malignancies, including
NSCLC and SCLC [90].
Subtype 9.1 overview
The IGF axis is important in normal cells for differentiation,
metabolism, and growth with features of endocrine, paracrine, and
autocrine control. Alterations in this pathway can lead to
uninhibited proliferation, playing an important role in the
development of neoplasia [90]. Expression of IGF1R in particular
appears to be a negative prognostic indicator – at least on
univariate analysis – and is seen in up to 31% of patients with
NSCLC [91,92]. The SOE score for testing for IGF aberrations or
IGF levels in lung cancer, however, is currently ‘low’ as much of
the data regarding this pathway is pre-clinical while several clinical
trials evaluating inhibition of this pathway have been negative or
are still ongoing [93,94].
Potential therapeutic approach for SUBTYPE 9.1
There are several therapeutic approaches to inhibiting the IGF
axis using monoclonal antibodies against the extracellular domain
of IGF1R as well as small-molecule inhibitors of the intracellular
tyrosine kinase domain of the same receptor [93,94,95].
Monoclonal antibodies. Multiple monoclonal antibodies
have been investigated in the treatment of lung cancer. One
such antibody, figitumumab, was shown to improve response rates
in both adenocarcinoma and squamous cell histologies when
combined with carboplatin and paclitaxel in a phase II trial [95].
However, the phase III trial was suspended due to increased
deaths and toxicity from heart failure and myocardial events in
those who received figitumumab [93]. The combination of
erlotinib with the IGF1R monoclonal antibody, R1507, did not
reveal a statistically significant improvement in PFS or OS in
NSCLC [94] though investigations with another IGFR1
monoclonal antibody, cixutumumab, in the treatment of SCLC
and NSCLC are currently ongoing [96,97].
IGF1R tyrosine kinase inhibitors. OSI-906 is a selective
small molecule, dual kinase inhibitor of both IGF1R and the
insulin receptor. A phase II clinical trial combining OSI-906 with
erlotinib in NSCLC is currently recruiting patients [98,99].
Discussion
Lung cancer treatment has traditionally been viewed within the
bounds of a ‘one-size-fits-all’ approach with the use of cytotoxic
chemotherapy. With such poor outcomes, it is no wonder that a
sense of nihilism has pervaded the management of these patients
over the last half-century. During the past decade, however,
research has shown that lung cancer is a molecularly-complex
amalgam of diseases with specific derangements leading to vastly
different outcomes and, more importantly, the chance to develop
effective, targeted treatment [3]. This paper represents an outline
of a ‘molecular disease model’ for lung cancer as was previously
performed by our group for melanoma [7]. The purpose of this
paper is to highlight the key molecular aberrations observed in
lung cancer, including those for which there is still only preclinical
data, with the hope of accelerating the process of translational
research by providing a dynamic conduit between basic science
researchers, clinical trialists, and treating physicians.
Currently, EGFR and K-ras mutational testing are already
common practices for most community oncologists [13] while
testing for the EML4-ALK translocation has recently become a
regular phenomenon outside of only tertiary, academic oncology
centers due to the FDA-approval of crizotinib [6,51]. The
development of effective chemotherapeutics which target the
EGFR pathway – erlotinib and gefitinib – took place over 15 years
while the targeting of the EML4-ALK translocation with crizotinib
has progressed steadily in less than a third of that time [4,5,6].
These targets that are actionable today are observed primarily in
adenocarcinoma. However, as researchers become more adept at
identifying key molecular changes and developing targeted
therapies for these mutations, the momentum of the development
process will only continue. This will allow for the development of
Molecular Subtypes of Lung Cancer
PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e31906therapies that target the other aberrations discussed here,
including those pathways relevant to other NSCLC histologies
and SCLC. The result will be the effective management of patients
based on the molecular profiles of their cancers.
This review has focused on the treatment of lung cancer based
on the targeted treatment of single gene or pathway alterations.
Some of these targets are actionable today. This is highlighted by
the online lung cancer therapy finder application that can be
accessed online (www.collabrx.com/lung), and is based upon the
lung cancer molecular disease model discussed here. By entering
the detailed characteristics of a patient’s tumor such as stage,
histology, and previously performed molecular testing, detailed
information can be generated including what is currently known
about this tumor subtype, what further molecular testing is
recommended, next steps in the management of said tumor, and if
any clinical trials are available for those patients who exhibit these
specific mutations. This is a powerful tool for physicians and
patients alike allowing for truly personalized care in an easy-to-use
and regularly-updated format.
Methods
The initial subtypes and associated practice guidelines defined
here were identified by consensus of a panel of recognized lung
cancer experts, and supported by detailed analysis of the peer-
reviewed scientific literature. Subtypes are defined based on the
status of key lung cancer genes/pathways and their combinations.
Each subtype is defined by one key oncogene/tumor suppressor
(such as EGFR for subtypes 1.1 to 1.3, and K-ras for subtype 2.1),
either by itself or in combination with others that play a supportive
role (such as EGFR activating mutations in exons 19 and 21 and
the exon 20 resistance mutation T790M in the case of subtypes
1.1, 1.2, and 1.3).
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